- Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
- Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
- Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
- Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
- Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
- Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
- Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
- Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
- Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
More ▼
Key statistics
On Wednesday, Oncolytics Biotech Inc (ONCY:NAQ) closed at 1.01, 14.38% above the 52 week low of 0.883 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.03 |
Low | 1.00 |
Bid | 0.99 |
Offer | 1.03 |
Previous close | 0.99 |
Average volume | 163.01k |
---|---|
Shares outstanding | 75.42m |
Free float | 72.48m |
P/E (TTM) | -- |
Market cap | 75.55m USD |
EPS (TTM) | -0.2945 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼